Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic

16 June 2020 (Last Updated June 18th, 2020 08:47)

Sponsored by Novotech Sponsored by Visit Company
Clinical Trial Continuity in Asia-Pacific during the COVID-19 pandemic

The leading Asia-Pacific biotech specialist CRO Novotech is releasing a series of webinars about the advantages of conducting clinical trials in the Asia-Pacific. Sites across the APAC region have quickly changed how they manage trials, and most remained able to deliver the clinical trial services their clients need.

Looking at the macro trends of what’s happened over the COVID-19 pandemic period from March through April 2020 there’s been a significant number of clinical trials that have been initiated in Asia Pacific versus North America. During this period, biotech companies have initiated more clinical trials in Asia and Australia/New Zealand than in North America.

Moreover, according to recent research, about 80% of institutions in the US have had a disruption in the ability to enrol new patients to their oncology clinical trials, versus only 40% disruption in the Asia region.

In Australia, there was a national approach led by the prime minister. He formed a national cabinet with our states and territories, and the key decisions came out very quickly. We had rapid border closures having learned from what was going on across Asia. Australia had a very high testing frequency that continues even today even with a low caseload is very low.

New Zealand was a little bit different; they went in a little bit harder. They are a bit stricter with their lockdown measures, as they were very quick about implementing lockdowns. They had about 10 cases reported, when the country went into severe lockdown, in terms of all businesses and schools closing. Again, they have also closed their borders.

In terms of regulatory guidance, Australia was very much governed by the regulations that were released by the FDA, and the EMA. But certainly, we needed our own local regulatory guidance to be followed. It really ended being a collaboration between the Department of Health, all our state and territory health departments, and our National Health and Medical Research Council which came together and released very thorough guidance on how we should approach continuing clinical trials. So, there was a lot of guidance around virtual EC meetings and many ethics committees would continue to meet once a month.

 

Free Whitepaper

The benefits of running clinical trials in Asia-Pacific for biotech companies

According to a recent report by Frost & Sullivan, the CRO market is expected to grow to $71.7 billion by 2024 – and a full 15% of that is allocated to the APAC region. The reasons for this are numerous, including:

  • locations outside of the traditional markets are needed
  • increasingly middle class and middle aged population is excellent for trials
  • smoother regulatory requirements, while still maintaining high quality
  • government financial incentives for FIH trials

In this white paper, Singapore-based Novotech shows with hard data and experience why running your clinical trial through a CRO in Asia-Pacific will save you money, get rid of communications issues by having a trial supervisor on the ground and get to market faster with the same quality. Download it now to read the full benefits and experience of biotechs who have run successful trials in the region.

Enter your details here to receive your free whitepaper.

By clicking the “Submit” button above, you accept and acknowledge that your data will be used as described in the Novotech (Australia) Pty Limited Privacy Policy.

We will also collect and use the information you provide for carefully considered and specific purposes, where we believe we have a legitimate interest in doing so, for example to send you communications about similar products and services we offer. We will always give you an option to opt out of any future communications from us. You can find out more about our legitimate interest activity in our privacy policy here. ‘We’ includes Verdict Media Limited and other GlobalData brands as detailed here.